Intralesional MMR Vaccine Shows Promise for Treating Resistant Pediatric Warts

The study included 51 pediatric patients with warts that had proven resistant to intralesional Candida antigen therapy. These patients were then treated with intralesional injections of the MMR vaccine. The results were encouraging, with 15.5% of the patients experiencing complete resolution of their warts. Additionally, 12% had a near-complete resolution, and 37% showed partial improvement.

One interesting finding from the study was that age seemed to play a role in treatment response. Patients under the age of 12 were more likely to respond positively to the MMR vaccine treatment. However, the number of MMR treatments did not significantly affect treatment response.

While this study has its limitations, such as its retrospective nature and relatively small sample size, it suggests that the intralesional MMR vaccine could be a viable and effective treatment option for pediatric warts that do not respond to conventional therapies. The findings also highlight the importance of exploring alternative treatments for stubborn skin conditions, particularly in cases where existing therapies have been ineffective.

This study suggests that the intralesional MMR vaccine could offer hope for patients dealing with stubborn pediatric warts. It emphasises the importance of exploring alternative treatments when initial therapies fail and highlights the potential benefits of early intervention, especially in younger patients. Further research may provide more insights into optimising this approach for the effective management of warts in children.

Reference: